Preparation method and application of ATAP polypeptide and vaccine thereof
By combining ATAP-M8 polypeptide with CD8 T cell epitopic peptides, targeting the mitochondria of cancer cells, the problem of insufficient in induction of immune response by existing vaccines is solved, and effective prevention and treatment of various cancers is achieved, with high safety and broad-spectrum anti-tumor effects.
Patent Information
- Application Number
- CN202410339834.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-25
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-03-25
AI Technical Summary
Existing cancer vaccines are not effective enough in inducing immune responses, making it difficult to effectively prevent and treat various types of cancer, especially without affecting normal cells.
The ATAP-M8 polypeptide is used to bind to the CD8 T cell epitope polypeptide, and apoptosis is induced by specifically targeting the mitochondria of cancer cells, thereby enhancing the immune response and preparing a vaccine for the prevention and treatment of cancer.
ATAP-M8 polypeptide can significantly enhance the immune response, quickly and effectively induce anti-tumor immunity, has broad-spectrum anti-tumor effects, is safe, can specifically target and kill a variety of cancer cells, and the metabolites are natural amino acids. Reduce damage to normal cells.
Smart Images

Figure QLYQS_1 
Figure QLYQS_2 
Figure QLYQS_3
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a method for preparing and applying an ATAP polypeptide and a vaccine thereof, and in particular relates to an application of an ATAP polypeptide vaccine in preventing cancer, and specifically relates to a use of an ATAP-CD8 T cell epitope polypeptide or a pharmaceutically acceptable salt thereof in preparing a drug for treating cancer. Background Art
[0002] ATAP (Amphipathic Tail-Anchoring Peptide) is a new type of amphipathic tail-anchoring peptide derived from Bfl-1 (amino acids 147-175). Experiments have shown that ATAP can specifically target mitochondria to trigger apoptosis. Compared with other mitochondrial-targeted peptide drugs, ATAP has the unique advantage of being able to independently induce effective apoptosis without relying on Bcl-2 family proteins. In particular, ATAP can permeate the mitochondrial membrane without the participation of Bax and Bak, which usually affect the function of the drug carrier and the expression of the drug carrier in cancer cells. In addition, ATAP-induced apoptosis is not affected by Bcl-2 or other anti-apoptotic family members, which are often overexpressed in cancer cells.
[0003] ATAP-M8 is a 38-amino acid peptide, which is optimized and modified from the natural ATAP sequence. In order to improve the physicochemical properties and promote clinical application, the natural ATAP sequence was subjected to amino acid substitution and chemical modification to improve its biological activity. ATAP-M8 is a fusion peptide obtained by fusion of the ATAP structure and the iRGD sequence after structural modification. The iRGD sequence can highly target and bind to the integrin receptor (Integrin) that is highly expressed on the surface of many tumor cells. ATAP-M8 can specifically recognize the cell mitochondrial membrane, and through the special amphipathic helical structure, it can be positioned to make holes in the mitochondrial membrane, physically destroy the mitochondrial structure, and induce cell apoptosis. By connecting ATAP to the internalized RGD peptide (iRGD), the selective targeting of ATAP to tumor cells is achieved. ATAP can effectively identify cancer cells and normal cells, and bring the peptide into the tumor cell area in a targeted manner, specifically killing tumor cells and reducing damage to normal cells.
[0004] The obtained modified peptide ATAP-M8 has the following sequence:
[0005]
[0006] Among them: an intramolecular disulfide bond is formed between the two Cys residues at amino acid positions 30 and 38.
[0007] The molecular weight is: 4375.20.
[0008] The structural formula is as follows:
[0009]
[0010] Cancer vaccines are one of the important means of tumor immunotherapy and are currently the most effective way to prevent and treat tumors. Finding safe, effective, and broad-spectrum cancer vaccines is a frontier and hot issue in scientific and technological innovation in the medical field. Therefore, the applicant attempted to study ATAP-M8-related anti-cancer vaccines. Summary of the invention
[0011] An object of the present invention is to solve at least the above problems and / or disadvantages and to provide at least the advantages which will be described hereinafter.
[0012] Another object of the present invention is to provide ATAP polypeptides.
[0013] Another object of the present invention is to provide a method for preparing ATAP polypeptide vaccine.
[0014] Another object of the present invention is to provide the use of the ATAP polypeptide or a pharmaceutically acceptable salt thereof in the preparation of a drug for preventing and treating cancer.
[0015] To this end, the technical solution provided by the present invention is:
[0016] ATAP polypeptide, which provides the effect of preventing and treating cancer, and the ATAP polypeptide is a protein of the following a) or b):
[0017] a) any one of the amino acid sequences shown in SEQ ID NO: 1, 2, 3, 4,
[0018]
[0019]
[0020] Among them, the two Cys residues at amino acid positions 30 and 38 in SEQ ID NO: 1, 2, 3, 4 form an intramolecular disulfide bond
[0021] b) A protein derived from a) having a cancer prevention effect, wherein the amino acid sequence in a) is substituted, deleted or added with one or more amino acids.
[0022] A medicine comprising one or more of the ATAP polypeptides or pharmaceutically acceptable salts thereof.
[0023] Preferably, in the medicine, the medicine is a vaccine.
[0024] A DNA molecule encoding the ATAP polypeptide.
[0025] A method for preparing an ATAP polypeptide vaccine comprises the following steps:
[0026] One or more ATAP polypeptides or pharmaceutically acceptable salts thereof as claimed in claim 1 are prepared to obtain a polypeptide mixture, and then the polypeptide mixture is mixed with an adjuvant of the same concentration in equal volumes to obtain an ATAP polypeptide vaccine.
[0027] Preferably, in the method for preparing the ATAP polypeptide vaccine, the adjuvant is: polyinosinic acid-polycytosine nucleotide or aluminum phosphate.
[0028] Preferably, in the method for preparing the ATAP polypeptide vaccine, the ATAP polypeptide is prepared into a 50 mg / ml solution using sterile water, and then prepared into a concentration of 15 mg / ml using PBS buffer to obtain the polypeptide mixture.
[0029] Use of the ATAP polypeptide or a pharmaceutically acceptable salt thereof in the preparation of a drug for preventing and treating cancer.
[0030] Preferably, the application includes application in preparing a vaccine for preventing cancer.
[0031] Preferably, in the application, the cancer is glioblastoma, esophageal squamous cell carcinoma, acute myeloid leukemia, liver cancer, gastric cancer, kidney cancer, ovarian cancer, lung cancer, breast cancer and colon cancer.
[0032] The present invention has at least the following beneficial effects:
[0033] Generally, short peptide vaccines only induce specific cytotoxic T lymphocytes (CTL) cells, and the immune response caused is not sufficient, so they need to be supplemented with correspondingly designed long peptides to enhance the immune response to achieve therapeutic effects. The ATAP polypeptide of the present invention is a 38-peptide, which has good anti-cancer activity itself. By binding to the CD8 T cell epitope polypeptide, it enhances the immune response and can more quickly and effectively induce the host to produce anti-tumor immunity after vaccination.
[0034] Other advantages, objectives and features of the present invention will be embodied in part through the following description, and in part will be understood by those skilled in the art through study and practice of the present invention. DETAILED DESCRIPTION
[0035] The present invention is further described in detail below in conjunction with embodiments so that those skilled in the art can implement the invention with reference to the description.
[0036] It should be understood that terms such as “having”, “including” and “comprising” used herein do not specify the existence or addition of one or more other elements or combinations thereof.
[0037] The inventor's previous studies have shown that ATAP-M8 can effectively inhibit a variety of human cancer cells, including glioblastoma, esophageal squamous cell carcinoma, acute myeloid leukemia, liver cancer, gastric cancer, kidney cancer, ovarian cancer, lung cancer (including non-small cell lung cancer), breast cancer, colon cancer, etc. 20 human cancer cells of different origins. Therefore, APAP-M8 has a broad-spectrum anti-tumor effect.
[0038] As a new type of peptide anti-tumor drug, ATAP-M8 has a unique mechanism of action. It can specifically target and kill mutated tumor cells, but is non-toxic to normal tissue cells, and has higher safety than other types of small molecule cytotoxic drugs. In addition, its metabolites are natural amino acids, which are nutrients needed by the human body. Animal experiments have shown that the safety window of ATAP-M8 is 98 times; the effective dose for humans is 7.5 mg, and the effective anti-tumor dose is 30 mg. At therapeutic doses, ATAP-M8, as an anti-tumor drug, can significantly kill cancer cells and inhibit tumor growth; at doses lower than the therapeutic dose, ATAP is administered by intravenous drip, and can specifically and accurately identify mutated tumor cells in human tissues in the blood circulation, and instantly kill the initial trace amount of mutated tumor cells. Therefore, ATAP-M8 can be used to prepare a broad-spectrum anti-tumor vaccine to prevent the generation of multiple mutated cancer cells.
[0039] The present invention provides an ATAP polypeptide, which provides the effects of preventing and treating cancer. The ATAP polypeptide is a protein of a), b), or:
[0040] a) any one of the amino acid sequences shown in SEQ ID NO: 1, 2, 3, 4,
[0041] b) A protein derived from a) having a cancer prevention effect, wherein the amino acid sequence in a) is substituted, deleted or added with one or more amino acids.
[0042] The applicant conducted CD4 T cell analysis on the mutant polypeptide sequence of tumor-related gene SWAP70. 8+ T cell epitope prediction, the top 4 mutant peptide sequences were selected, which are:
[0043] KYQGLVVKQSV
[0044] DYVTGKMAV
[0045] YGLFSTFYM
[0046] GLFSTFYMR
[0047] The four mutant polypeptide sequences were synthesized into polypeptide fragments respectively, and then the four polypeptide fragments were connected to ATAP and then mixed with adjuvants. The amino acid sequences are shown in SEQ ID NOs: 1, 2, 3, and 4.
[0048]
[0049] (SEQ ID NO: 1, 2, 3, 4 from top to bottom)
[0050] The present invention also provides a medicine comprising one or more of the ATAP polypeptides or pharmaceutically acceptable salts thereof.
[0051] In some embodiments of the present invention, the drug is a vaccine, and the ATAP polypeptide vaccine comprises one or more of the ATAP polypeptides or pharmaceutically acceptable salts thereof.
[0052] The present invention also provides a DNA molecule, wherein the DNA molecule encodes the ATAP polypeptide.
[0053] The present invention also provides a method for preparing an ATAP polypeptide vaccine, comprising the following steps:
[0054] One or more ATAP polypeptides or pharmaceutically acceptable salts thereof as claimed in claim 1 are prepared to obtain a polypeptide mixture, and then the polypeptide mixture is mixed with an adjuvant of the same concentration in equal volumes to obtain an ATAP polypeptide vaccine.
[0055] In the above scheme, preferably, the adjuvant is: polyinosinic acid-polycytosine nucleotide or aluminum phosphate.
[0056] In the above scheme, preferably, the ATAP polypeptide is prepared into a 50 mg / ml solution using sterile water, and then prepared into a concentration of 15 mg / ml using PBS buffer to obtain the polypeptide mixture.
[0057] The present invention also provides the use of the ATAP polypeptide or a pharmaceutically acceptable salt thereof in the preparation of a drug for preventing and treating cancer.
[0058] In the above scheme, preferably, the application includes application in the preparation of a vaccine for preventing cancer.
[0059] In the above scheme, preferably, the cancer is glioblastoma, esophageal squamous cell carcinoma, acute myeloid leukemia, liver cancer, gastric cancer, kidney cancer, ovarian cancer, lung cancer, breast cancer and colon cancer.
[0060] Due to its unique mechanism of precisely targeting mutant tumor cells, as well as its safe, efficient, and broad-spectrum anti-tumor effects, ATAP-M8 can be used as a cancer vaccine. Under safe dosage conditions, it can be administered by intravenous drip 1-2 times a year to effectively kill the initial tumor mutant cells in the body and achieve the effect of preventing cancer.
[0061] The present invention relates to the use of polypeptides shown in SEQ ID NOs: 1-4 or pharmaceutically acceptable salts thereof in the preparation of vaccine drugs for preventing cancer, wherein the cancer is selected from glioblastoma, esophageal squamous cell carcinoma, acute myeloid leukemia, liver cancer, gastric cancer, kidney cancer, ovarian cancer, lung cancer (including non-small cell lung cancer), breast cancer and colon cancer, etc., and is a tumor cell type with high expression of integrin receptors.
[0062] The present invention also relates to the use of a pharmaceutical composition containing a polypeptide shown in SEQ ID NO: 1-4 or a pharmaceutically acceptable salt thereof in the preparation of a vaccine drug for preventing cancer, wherein the cancer is selected from liver cancer, gastric cancer, kidney cancer, ovarian cancer, lung cancer (including non-small cell lung cancer), breast cancer and colon cancer.
[0063] In the present invention, the polypeptides shown in SEQ ID NO. 1-4 or pharmaceutically acceptable salts thereof can be used alone as vaccine active ingredients for preventing cancer, or can be used in combination with additional pharmaceutically active compounds for preventing and treating cancer.
[0064] The polypeptides shown in SEQ ID NOs: 1-4 of the present invention can be prepared using the Fmoc solid phase synthesis method.
[0065] In the present invention, the unit "M" represents mol / L, and "μM" represents μmol / L.
[0066] In the present invention, "pharmaceutically acceptable salt" refers to a salt that retains the desired biological activity of the target compound and exhibits minimal undesirable toxicological effects. These pharmaceutically acceptable salts can be prepared in situ during the final isolation and purification of the compound or by reacting the purified compound in its free acid or free base form with a suitable base or acid, respectively.
[0067] The dosage and method of use of the polypeptide of the present invention depend on many factors, including the patient's age, weight, sex, natural health, nutritional status, activity strength of the compound, time of administration, metabolic rate, severity of the disease, and subjective judgment of the treating physician. The preferred dosage is between 0.001-100 mg / kg body weight / day. The dosage is administered as a single dose per day or as several sub-doses per day, for example, 2, 3, 4, 5 or 6 doses per day. Alternatively, the administration may be intermittent, for example, once every other day, once a week, or once a month. The therapeutically effective amount of a salt or solvate, etc., can be determined as the ratio of the therapeutically effective amount of the polypeptide itself.
[0068] In some embodiments, the pharmaceutical composition may optionally further comprise one or more additional pharmaceutically active compounds.
[0069] According to the present invention, the pharmaceutical composition comprises the polypeptide of the present invention and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition can be administered by, for example, oral or parenteral routes. The pharmaceutical composition of the present invention can be prepared into various dosage forms according to conventional methods in the art, including but not limited to tablets, capsules, solutions, suspensions, granules or injections, and administered by, for example, oral or parenteral routes.
[0070] The pharmaceutical composition of the present invention can exist in a unit dosage form containing a predetermined amount of active ingredient per unit dose. Such a unit can contain 0.001-1000 mg, for example, 0.05 mg, 0.1 mg, 0.5 mg, 1 mg, 2 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg, 25 mg, 27.5 mg, 30 mg, 35 mg, 37.5 mg, 40 mg, 42.5 mg, 45 mg, 47.5 mg, 50 mg, 60 mg, 70 mg, 80 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 500 mg, 750 mg or 1 g of the compound of the present invention, depending on the disease treated, route of administration and age, body weight and symptoms of the subject, or the pharmaceutical composition can exist in a unit dosage form containing a predetermined amount of active ingredient per unit dose. In another embodiment, the unit dosage compositions are those containing a daily dose or sub-dose as herein described, or an appropriate fraction thereof, of an active ingredient.Alternatively, such pharmaceutical compositions may be prepared by any method well known to those skilled in the art.
[0071] The embodiments of the present invention will be described in detail below in conjunction with the examples, but those skilled in the art will appreciate that the following examples are only used to illustrate the present invention and should not be considered to limit the scope of the present invention. If no specific conditions are specified in the examples, they are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be obtained commercially.
[0072] Example 1 In vitro pharmacodynamic evaluation
[0073] The in vitro proliferation inhibition effect of the polypeptides shown in SEQ ID NO: 1-4 on human tumor cells and normal tissue cells from different tissue sources was evaluated. The tumor cell lines and human normal liver cells used in this example were all from the cell bank of Zhejiang University School of Pharmacy.
[0074] Cell culture and inoculation: The tumor cell lines used in the experiment were cultured in RPMI1640 culture medium (HyClone, SH30809.01B, 500 ml) containing 10% serum, 100 IU / mL penicillin and 100 IU / mL streptomycin, and cultured in a 37°C, 5% CO2 incubator. A certain amount of tumor cells were inoculated into a white 96-well culture plate according to the cell growth rate.
[0075] Drug administration: The experiment set up a test drug group and a positive control group. Each test drug group was set up with 8 concentration gradients, half-dilution, and three replicates for each concentration. The highest starting concentration of the test drug was 100 μM. The experiment was repeated three times.
[0076] CellTiter assay: After the test drug and positive control acted on the cells for 48 hours, 50 μL of CellTiter-Glo reagent (purchased from Promega) was added to each well. Incubate at room temperature in the dark for 10 minutes, and detect the chemiluminescent signal with an enzyme reader (SpectraMax M5, purchased from Molecular Devices). Record the results, draw a cell growth curve with drug concentration as the horizontal axis and absorbance as the vertical axis, and calculate IC 50 value.
[0077] Result processing:
[0078] According to the OD value measured by the microplate reader, the inhibition rate was calculated according to the following formula:
[0079] Inhibition rate (%) = (1-OD 给药 / OD 对照 )×100%,
[0080] If the inhibition rate is ≤0%, it is recorded as 0%.
[0081] Calculation IC 50,The experiment was repeated three times, and the mean and standard deviation were calculated. The data were expressed as: mean ± standard deviation. The experimental results are shown in Table 1.
[0082] Table 1 Inhibitory effect of ATAP-M8 on tumor cell proliferation
[0083]
[0084] Note: NA:>100nM.
[0085] The test substances SEQ ID NO: 1-4 showed broad-spectrum anti-tumor activity: they had significant proliferation inhibition effects on 20 human tumor cells from different tissues, with a half inhibitory concentration (IC 50 ) is between 0.83μM and 9.92μM.
[0086] Example 2 Effects of SEQ ID NOs: 1-4 on mitochondrial damage and apoptosis in gastric cancer HGC27 cells
[0087] The results of flow cytometry showed that the anti-tumor sensitivity of SEQ ID NO: 1-4 was positively correlated with the expression of IntegrinαVβ3 on the surface of tumor cells, that is, the higher the expression of IntegrinαVβ3 in tumor cells, the stronger the sensitivity to ATAP-M8. 50 The lower.
[0088] SEQ ID NO: 1-4 (5, 10 and 20 μM) can induce the decrease of mitochondrial membrane potential of gastric cancer cell HGC27 cells with high expression of IntegrinαVβ3 in a concentration-dependent manner after 4 hours of action, and the JC-1 green fluorescence cell ratios are 11.39±6.70%, 33.32±7.55%, 34.70±5.49% (negative control Control 11.94±6.77%), and the apoptosis rate of positive control Taxol is 5.93±1.93%. Under the same conditions, there is no significant decrease effect on intestinal cancer HT29 cells with low expression of IntegrinαVβ3, and the JC-1 green fluorescence cell ratios are 5.34±3.22%, 5.74±1.08%, 11.60±6.50% (negative control Control 3.50±1.80%), and the apoptosis rate of positive control Taxol is 7.10±5.31%.
[0089] SEQ ID NO: 1-4 (5, 10 and 20 μM) induced apoptosis of gastric cancer cell HGC27 cells with high expression of IntegrinαVβ3 in a concentration-dependent manner. The apoptosis rates of the drug at 24 hours were 16.06±4.37%, 29.50±11.61%, 41.85±25.42% (negative control Control 11.34±1.82%), and the apoptosis rate of the positive control Taxol was 33.32±18.09%. The apoptosis rates of SEQ ID NO: 1-4 at 48 hours were 11.86±6.65%, 30.70±5.95%, 53.98±17.93% (negative control Control 8.69±4.45%), and the apoptosis rate of the positive control Taxol was 60.20±9.53%. However, ATAP-M8 (5, 10 and 20 μM) did not induce apoptosis in HT-29 cells with low expression of IntegrinαVβ3. The apoptosis rates after 24 hours were 7.11±3.19%, 6.79±2.53%, 10.03±2.99% (Control 7.95±0.73%), and the apoptosis rate of the positive control Taxol was 25.69±16.47%. The apoptosis rates of SEQ ID NO: 1-4 after 48 hours were 6.79±2.37%, 7.60±2.33%, 9.51±3.99% (negative control Control 5.04±2.06%), and the apoptosis rate of the positive control Taxol was 33.19±17.10%.
[0090] Example 3 In vivo antitumor pharmacodynamics evaluation
[0091] The experimental therapeutic effects of different doses of the polypeptide represented by SEQ ID NO: 1 on subcutaneous transplanted tumors of human tumor cells in nude mice were evaluated.
[0092] Nude mouse transplant tumor model establishment: Different human cancer cells (cell bank of Zhejiang University School of Pharmacy) were used to evaluate the in vivo anti-tumor activity. 7 Individual tumor cells were injected into the armpits of nude mice (purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.). After the tumor characteristics stabilized (generally 2-3 generations), the tumor mass of the breeding mouse was removed and placed in a glass dish filled with physiological saline. The surface blood vessels were removed, and the necrotic area was removed and the tumor mass was cut into 1-2 mm 3 , a trocar was used to access the left armpit of the nude mouse.
[0093] Animal grouping and drug administration: When the tumor grows to an average volume of 100-300mm 3 Afterwards, 5 to 6 mice per group.
[0094] Data measurement and processing: Weigh and measure tumor volume twice a week. On the day after the last administration, weigh and measure tumor volume, then sacrifice nude mice and weigh tumor masses. Calculate relative tumor volume (RTV), relative tumor proliferation rate (T / C) and tumor inhibition percentage (IR) for statistical analysis. Take photos of tumor tissues and record.
[0095] Data measurement and statistics:
[0096] Weigh and measure tumor volume twice a week for 21 days. On the 22nd day, weigh and measure tumor volume, then sacrifice nude mice and weigh tumors. Calculate relative tumor volume (RTV), relative tumor proliferation rate (T / C) and tumor inhibition percentage (IR) for statistical analysis. The calculation formula is as follows:
[0097] (1) Tumor volume: TV = 1 / 2 × a × b 2 , where a and b represent the length and width of the tumor, respectively (cm);
[0098] (2) Tumor volume ratio: RTV (relative tumor volume) = V t / V0, where V0 is the tumor volume measured at the time of group administration (i.e., d0), and Vt is the tumor volume at each measurement;
[0099] (3) Relative tumor growth rate: T / C (%) = T RTV / C RTV × 100%, where T RTV is the RTV of the treatment group, C RTV is the RTV of the solvent control group;
[0100] (4) Tumor inhibition rate: IR (%) = (1-TW t / TW c )×100%, where TW t is the tumor weight of the treatment group, TW c is the tumor weight of the solvent control group.
[0101] (5) Tumor Growth Inhibition value (TGI). It is used to evaluate the inhibitory effect of the test drug on tumor growth in vivo (i.e., animal experiments). TGI = (1-tumor weight of the treatment group / tumor weight of the control group) * 100%
[0102] Therapeutic effect evaluation criteria: T / C (%)>40%, IR (%)≤60% were considered ineffective; T / C (%)≤40%, IR (%)≥60%, and p<0.05 after statistical analysis were considered effective.
[0103] Experimental results: see Table 2
[0104] Table 2 Experimental therapeutic effects of ATAP peptide on nude mouse transplanted tumors with different human tumors
[0105]
[0106]
[0107] SEQ ID NO: 1-4 selectively induces a decrease in mitochondrial membrane potential of tumor cells with high expression of IntegrinαVβ3, damages mitochondria, and induces apoptosis of tumor cells, thereby exerting an anti-tumor effect. In vitro experiments showed that SEQ ID NO: 1-4 exhibited broad-spectrum anti-tumor activity, with a half inhibitory concentration (IC 50 ) are all less than 10 μM. In vivo experiments showed that SEQ ID NO: 1-4 can inhibit a variety of human tumors in nude mice in a dose-dependent manner, and have significant therapeutic effects on gastric cancer, prostate cancer, osteosarcoma and breast cancer. The minimum effective dose for sensitive tumor strains is 5.0 mg / kg.
[0108] Example 4 Toxicity test of SEQ ID NO: 1 in cynomolgus monkeys injected intravenously for four weeks
[0109] Purpose of the test
[0110] Cynomolgus monkeys were given SEQ ID NO: 1 by intravenous injection for 4 weeks, followed by a 4-week recovery period after drug withdrawal, to observe the nature, extent, dose-effect, time-effect relationship and reversibility of toxic reactions that may be caused by the test article, to determine the toxic target organs or tissues, and to study its toxicokinetics to understand the relationship between exposure dose and toxicological results in toxicity studies.
[0111] Experimental animals
[0112] Species: Cynomolgus monkey;
[0113] Level: Ordinary;
[0114] Number and gender of animals purchased and used: 40, half male and half female;
[0115] Age: 3-5 years old;
[0116] Body weight: The body weight during the adaptation period was 2.40-4.10 kg. The average body weight during the experimental grouping was 3.01 kg. Except for a few animals, the individual body weight values of the other animals were within the range of ±20% of the mean of the same sex.
[0117] Source: Guangxi Guidong Primate Development Experiment Co., Ltd. (Production License No.: SCXK Gui 2016-0001). Quality certificate issued and printed by: Guangxi Zhuang Autonomous Region Science and Technology Department. Quality certificate No.: 45001200000334;
[0118] Animal Grouping
[0119] Group design: control group, SEQ ID NO: 1 low, medium, and high dose groups;
[0120] Number of animals: 10 / group, 40 in total;
[0121] Gender ratio: half male and half female;
[0122] Grouping method: The monkeys were randomly grouped according to their weight and gender using the PRISTIMA version 7.2.0 data system;
[0123] Dosage design
[0124] The effective dose of SEQ ID NO: 1 in the mouse tumor-bearing model is 5 mg / kg / day, which is converted into an equivalent dose of 1.25 mg / kg / day in cynomolgus monkeys.
[0125] This study designed ATAP-M8 low, medium and high dose groups, 3, 10 and 30 mg / kg respectively. A control group was also set up, where an equal volume of 0.9% sodium chloride injection was intravenously injected.
[0126] The specific dosage design is shown in Table 3.
[0127] Table 3 Dosage design table
[0128]
[0129]
[0130] Drug administration
[0131] Route of administration: intravenous injection;
[0132] Reasons for selecting the route of administration: consistent with the intended clinical route;
[0133] Dosing frequency and cycle: once a day for 4 consecutive weeks, with a 4-week recovery period;
[0134] Administration site: administration into the bilateral upper limb veins and lower limb veins (can be alternated between left and right);
[0135] Dosing volume: 15mL / kg;
[0136] Drug delivery rate: set to 2 mL / min (±0.3 mL / min deviation allowed, using a microinjection pump for delivery);
[0137] Dosing syringe: syringe specification 50mL, syringe batch number 180106;
[0138] Note: Except for the control group, the new syringes used for drug administration in each group can be rinsed with a certain amount of the drug administration preparation of the test sample of corresponding concentration before use;
[0139] The dosage for each animal was adjusted based on the most recently measured body weight.
[0140] The day of first dosing was defined as trial day 1.
[0141] in conclusion:
[0142] Under the conditions of this experiment, cynomolgus monkeys were intravenously injected with SEQ ID NO: 1 at doses of 3, 10, and 30 mg / kg for 4 consecutive weeks, and the drug was discontinued for 4 weeks. In the 30 mg / kg group, the main findings were a decrease in adrenal zona fasciculata vacuoles, foamy macrophage infiltration in the spleen and lymph nodes, increased serum ALT, AST, Urea, and Crea, a slight decrease in peripheral blood red blood cells, WBC, and LYM, and a decrease in PLT and bone marrow plate-producing cells in some monkeys. After 4 weeks of discontinuation of the drug, the adrenal lesions in the 30 mg / kg group were partially recovered. In addition, no obvious abnormal changes were observed in the body temperature, blood pressure, II-lead electrocardiogram, circulating immune complexes, immunoglobulins, lymphocyte subsets, cytokines, and ophthalmic examinations of the monkeys in each group.
[0143] Within the dosage range of 3-30 mg / kg, there was no significant gender difference in the exposure of SEQ ID NO: 1 in plasma, and the increase in exposure was lower than the dose increase ratio. There was no accumulation after 4 weeks of continuous administration.
[0144] Cynomolgus monkeys were given SEQ ID NO: 1.4 weeks of intravenous injection, with the highest no-serious-toxicity dose (HNSTD) of 30 mg / kg (after the last dose, the average AUC of ATAP-M8 in female monkeys was 133 h.μg / mL, and in male monkeys was 147 h.μg / mL), and the no-toxic-effect dose (NOAEL) was 10 mg / kg (after the last dose, the average AUC of ATAP-M8 in female monkeys was 262 h.μg / mL, and in male monkeys was 274 h.μg / mL).
[0145] Example 5 SEQ ID NO: 1. Genotoxicity
[0146] Under the conditions with or without the S9 metabolic activation system, 50, 150, 500, 1500, and 5000 μg / dish of SEQ ID NO: 1 did not cause gene mutations in all tested strains, that is, the Ames test results were negative.
[0147] After exposure to the S9 metabolic activation system for about 4 hours, 80, 200, and 500 μg / mL of ATAP-M8 did not cause a significant increase in the rate of chromosome structural aberrations in CHL cells; after exposure to the S9 metabolic activation system for about 24 hours, 32, 80, and 200 μg / mL of ATAP-M8 did not cause a significant increase in the rate of chromosome structural aberrations in CHL cells. The results of the in vitro chromosomal aberration test of ATAP-M8 in CHL cells were negative.
[0148] NIH mice were intravenously injected with 6.25, 12.5, and 25 mg / kg of ATAP-M8 once a day for 3 consecutive days. It did not cause damage to the chromosomal integrity of bone marrow cells or abnormal chromosome segregation. The results of the bone marrow micronucleus test of ATAP-M8 mice were negative.
[0149] Example 6 Preparation of ATAP polypeptide vaccine
[0150] A method for preparing an ATAP polypeptide vaccine comprises the following steps:
[0151] Take the ATAP polypeptides described in SEQ ID NO: 1-4 respectively, prepare the four ATAP polypeptides into 50 mg / ml solutions with sterile water, and then prepare them into 15 mg / ml with PBS buffer to obtain four polypeptide mixtures, and then mix the four polypeptide mixtures with adjuvants of the same concentration in equal volumes to obtain four ATAP polypeptide vaccines. The adjuvant is: polyinosinic acid-polycytosine nucleotide or aluminum phosphate.
[0152] Example 7. SEQ ID NO: 1-4 polypeptide vaccines induce specific cytotoxic T (CTL) responses.
[0153] 1.1 Induction of PBMC antigen-specific effector CTL responses in vitro
[0154] Preparation of peripheral blood mononuclear cells (PBMC): peripheral blood was obtained from healthy subjects and separated by gradient centrifugation using polysucrose-diatrizoate. The number of cells was 5 × 10 5 ml / L. PBMCs were stimulated with SEQ ID NO: 1-4 peptides for 3 times, with a final peptide concentration of 5 nmol / ml, once every 5 days, and IL-2 30 U / ml was added the next day. On the 4th day after the end, the supernatant was collected for IFN-γ detection.
[0155] Adoption standards 51 Cr release test to detect specific CTL cytotoxic effect: T2 cells or Caski cells were used as target cells, and PBMC were collected as effector cells after 6 days. Peptide samples were added to make the final mass concentration of 5nmol / ml, Caski cells were washed, and the cell number was 5×105 ml / L was used as target cells.
[0156] According to the test results:
[0157] (1) When epitope peptide-loaded T2 cells were used as target cells, SEQ ID NO: 1-4 polypeptides all induced strong CTL activity (P < 0.01, compared with the control group), among which SEQ ID NO: 4 polypeptide had the strongest effect (P < 0.05, compared with SEQ ID NO. 1-3 group).
[0158] (2) In the control experiment, T2 cells without epitope peptide loading were used as target cells, and the specific lysis rate of CTL induced by the polypeptides of SEQ ID NO: 1-4 was less than 10%.
[0159] (3) Caski cells were used as target cells. CTLs generated by in vitro induction with polypeptides of SEQ ID NO: 1-4 were able to kill Caski cells (P<0.01, compared with the control group).
[0160] As shown in Table 4:
[0161]
[0162] 1.2 Induction of antigen-specific effector CTL responses in vivo
[0163] Female transgenic mice aged 10 weeks were selected and randomly divided into 7 groups, with 10 mice in each group. The mice were injected with SEQ ID NO: 1-4 polypeptides fully emulsified with Freund's adjuvant (IFA) at the base of the tail at a dose of 10 nmol per mouse. The control group was injected with the same concentration of ATAP and phosphate buffered saline (PBS) fully emulsified with IFA, and boosted with one immunization one week later.
[0164] The spleen of mice was taken 10 days after the last immunization to prepare splenocytes, with a cell number of 5×10 5 ml -1 The final concentration of the polypeptide was 2 nmol / ml. The next day, 30 U / ml of IL-2 was added and the cells were incubated at 37°C and 5% CO2 for 4 days to detect IFN-γ.
[0165] 51 Cr release assay to detect specific CTL cytotoxicity: After 10 days, the cells were collected and used as effector cells. b The cell line was used as the target cell, the peptide sample concentration was 10 nmol / ml, incubated for 100 minutes, at 37°C, 5% CO2, and the cell number was 5×10 5 ml -1 .
[0166] The experimental test results show that:
[0167] (1) JurkatA2.1 / K loaded with epitope peptide b SEQ ID NO: 4 induced strong CTL activity for the target cells. When E / T = 100: 1, the target cell specific lysis rate was 78.0% (P < 0.01, compared with the control group and SEQ ID NO: 1-3 groups); NO. 1-3 also induced CTL activity. When E / T = 100: 1., the target cell specific lysis rate was 58-62% (P < 0.01, compared with the control group).
[0168] (2) JurkatA2.1 / K without epitope peptide loading b The specific lysis rate of CTL induced by the polypeptides of SEQ ID NO: 1-4 against target cells was less than 10%.
[0169] As shown in Table 5:
[0170]
[0171] Example 8. Detection of extracellular IFN-γ of SEQ ID NO. 1-4 polypeptide vaccine
[0172] 2.1. ELISpot (ELI-Spot) assay
[0173] The ELI-Spot assay can detect the number of cells secreting IFN-γ at the single cell level. Activated T lymphocytes secrete high concentrations of IFN-Y cytokines around them, so enzyme-linked immunosorbent assay can be used to count the number of cytokine-secreting cells. The ELI-Spot assay is used to detect the number of cells secreting IFN-γ after PBMCs are stimulated with peptides.
[0174] EL1-Spot detection of antigen-specific CTL of IFN-γ Lymphocytes were added to the EL1-Spot detection plate at a dosage of 3×10 5 cells / well, add stimulants to a final concentration of 10 μg / mL, incubate for 30 h, and perform subsequent operations according to the instructions of ELl-Spot; scan the plate with an immunospot analyzer, record the number of spots, and perform statistical analysis.
[0175] The test results showed that SEQ ID NO: 1-4 polypeptides can effectively stimulate peripheral blood mononuclear cells (PBMC) to produce IFN-γ secreting cells (P < 0.01, compared with the control group), among which SEQ ID NO. 4 has the strongest effect, and the values of blank group PBS and original drug ATAP are very small.
[0176] Table 6. ELI-Spot method to analyze the amount of IFN-γ secreted by cells
[0177]
[0178] *P<0.01, compared with the control group, # P<0.01, compared with SEQ ID NO:1-3.
[0179] 2.2. Detection of extracellular IFN-γ secretion
[0180] The concentration of extracellular IFN-γ can reflect the proliferation of IFN-γ secreting cells. The IFN-γ secretion value of each group can be calculated according to the standard curve. From the ELISA measurement values, it can be seen that SEQ ID NO: 1-4 polypeptides all induced PBMC to secrete IFN-γ (P<0.01, compared with the control group), among which SEQ ID NO: 3 had the strongest effect, and the values of blank group PBS and original drug ATAP were very small.
[0181] Table 7. Detection of extracellular IFN-γ secretion of PBMC
[0182]
[0183] *P<0.01, compared with the control group, # P<0.01, compared with SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.4.
[0184] Data analysis The experimental data were expressed as mean ± standard deviation (mean ± SD) and plotted using Graphpad software. One-way ANOVA was used to perform statistical analysis of the experimental data, and t-test was used to compare the differences between the groups. P < 0.05 was considered to be a significant difference between the two groups.
[0185] The number of modules and processing scales described here are used to simplify the description of the present invention. Applications, modifications and variations of the present invention are obvious to those skilled in the art.
[0186] Although the embodiments of the present invention have been disclosed as above, they are not limited to the applications listed in the specification and the implementation modes. They can be fully applied to various fields suitable for the present invention. For those familiar with the art, additional modifications can be easily implemented. Therefore, without departing from the general concept defined by the claims and the scope of equivalents, the present invention is not limited to specific details.
Claims
1. ATAP polypeptide, wherein the ATAP polypeptide provides the effects of preventing and treating cancer, characterized in that: The ATAP polypeptide is Any one of the amino acid sequences shown in SEQ ID NO: 1, 2, 3, 4, SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 3 SEQ ID NO: 4 Among them, an intramolecular disulfide bond is formed between the two Cys residues at amino acid positions 30 and 38 in SEQ ID NO: 1, 2, 3, and 4.
2. A drug, characterized in that It comprises one or more ATAP polypeptides or pharmaceutically acceptable salts thereof as claimed in claim 1.
3. The drug according to claim 2, characterized in that The medicine is a vaccine.
4. A DNA molecule encoding the ATAP polypeptide according to claim 1.
5. A method for preparing an ATAP polypeptide vaccine, characterized in that: The steps include: One or more ATAP polypeptides or pharmaceutically acceptable salts thereof as claimed in claim 1 are prepared to obtain a polypeptide mixture, and then the polypeptide mixture is mixed with an adjuvant of the same concentration in equal volumes to obtain an ATAP polypeptide vaccine.
6. The method for preparing the ATAP polypeptide vaccine according to claim 5, characterized in that: The adjuvant is: polyinosinic acid-polycytosine nucleotide or aluminum phosphate.
7. The method for preparing the ATAP polypeptide vaccine according to claim 5, characterized in that: The ATAP polypeptide was prepared into a 50 mg / ml solution using sterile water, and then prepared into a concentration of 15 mg / ml using PBS buffer to obtain the polypeptide mixture.
8. Use of the ATAP polypeptide or a pharmaceutically acceptable salt thereof according to claim 1 in the preparation of a medicament for preventing and treating cancer.
9. The use according to claim 8, characterized in that The application includes application in preparing vaccines for preventing cancer.
10. The use according to claim 8, characterized in that The cancers are glioblastoma, esophageal squamous cell carcinoma, acute myeloid leukemia, liver cancer, gastric cancer, kidney cancer, ovarian cancer, lung cancer, breast cancer and colon cancer.
